Banyan Biomarkers has licensed its intellectual property related to traumatic brain injury (TBI) biomarkers to Abbott for assessment and verification .
The terms of the in a pharma licensing agreement were not disclosed.
Detecting concussions is often difficult because the physical damage may not be obvious, a CT scan is often normal and symptoms can be similar to those of other medical conditions. Failure to make a correct diagnosis may have serious implications for the patient.
In fact, the research indicates that repetitive head injury may lead to chronic traumatic encephalopathy (CTE) which shares many features of Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS).
For further deal information visit Current Agreements (subscription required)
Report: Partnering Agreements with Abbott 2009-2014
Report: Traumatic Brain Injury Partnering 2009-2014
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity